首页 > 市场调查报告书 > 医疗设备

医学影像诊断分子呈像/呈影剂

市场调查报告书

商品编码

1562474

比较显影剂市场规模、份额、成长分析，按类型、形式、方式、途径途径、地区 - 产业预测，2024-2031 年

Contrast Media Market Size, Share, Growth Analysis, By Type, By Form, By Modality, By Route of Administration, By Region - Industry Forecast 2024-2031

出版日期: 2024年09月13日 | 出版商:

SkyQuest | 英文 260 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球显影剂市场规模将为61亿美元，从2023年的65.5亿美元成长到2031年的116亿美元，在预测期内（2024-2031年）预计复合年增长率为7.4%。

复杂合併症和慢性疾病的增加扩大了超音波、X 光、MRI 和电脑断层扫描等诊断影像的使用。例如，美国FDA 于 2019 年 11 月核准了GE Healthcare 的大环 MRI显影剂Clariscan。这些创新对于确定手术全期扫描和介入的需求至关重要，并有助于市场扩张。根据国家卫生委员会的数据，2019 年约有 8,100 万美国患有多种慢性病，凸显了这些疾病的显着盛行率。据预测，在不久的将来，大约有1.57亿美国将受到慢性病的影响。慢性病在老年人中尤其普遍：根据国家老化委员会的数据，大约 80% 的 65 岁以上的人至少患有一种慢性病，近 70% 的医疗保险受益人患有多种慢性病。到 2034 年，预计将有约 7,700 万美国人年满 65 岁或以上。此外，心臟衰竭作为美国的首要死因，正变得越来越普遍。美国心臟协会的报告称，2019年约有65.9万名美国死于心血管疾病，预计2031年心臟病患者数量将增加46%。预计这些趋势将在预测期内推动全球市场对显影剂的需求。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

GE Healthcare（US）
Bracco Imaging SpA（Italy）
Bayer AG（Germany）
Guerbet（France）
Lantheus Medical Imaging（US）
Unijules Life Sciences Ltd.（India）
JB Chemicals & Pharmaceuticals Limited（India）
Taejoon Pharm Co., Ltd.（South Korea）
Jodas Expoim（India）
Imax Diagnostic Imaging Limited（Ireland）
Yangtze River Pharmaceutical Group（China）
Livealth Biopharma（India）
Beijing Beilu Pharmaceutical Co., Ltd.（China）
Unispire Biopharma Private Limited（India）
Arco Lifesciences（I）Pvt. Ltd.（India）
Stanex Drugs & Chemicals Pvt. Ltd.（India）
Rege Imaging & Cine Films Private Limited（India）
K Diam Exim（India）
Onko Ilac San. ve Tic. AS（Turkey）
Fresenius Kabi（Germany）
Biem Ilac San. ve Tic. AS（Turkey）
Advacare Pharma（US）

简介目录

Product Code: SQMIG35B2070

Global Contrast Media Market size was valued at USD 6.10 billion in 2022 and is poised to grow from USD 6.55 billion in 2023 to USD 11.60 billion by 2031, growing at a CAGR of 7.4% during the forecast period (2024-2031).

The increasing prevalence of complex comorbidities and chronic illnesses is driving the growing use of diagnostic imaging procedures, including ultrasound, X-rays, MRI, and CT scans. For instance, the U.S. FDA approved GE Healthcare's Clariscan, a macrocyclic MRI contrast agent, in November 2019. Such innovations are crucial for determining the need for perioperative scans and interventions, contributing to market expansion. According to the National Health Council, approximately 81 million Americans had multiple chronic conditions in 2019, highlighting the significant prevalence of these diseases. Projections suggest that nearly 157 million Americans will be affected by chronic illnesses in the near future. Chronic diseases are particularly prevalent among older adults, with about 80% of individuals aged 65 and older having at least one chronic illness, and nearly 70% of Medicare recipients managing multiple conditions, according to the National Council on Aging. By 2034, it is anticipated that approximately 77 million Americans will be 65 or older. Additionally, heart failure, a major cause of death in the U.S., is becoming increasingly common. The American Heart Association reports that around 659,000 Americans died from cardiovascular disorders in 2019, and the number of heart disease cases is expected to rise by 46% by 2031. These trends are expected to drive the demand for contrast media in the global market over the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Contrast Media market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contrast Media Market Segmental Analysis

Global Contrast Media Market is segmented by Type, Form, Modality, Route of Administration, Indication, Application, End User, and region. Based on Type, the market is segmented into Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media, and Barium-based Contrast Media. Based on Form, the market is segmented into Liquid Contrast Media, Powder Contrast Media, and Other Forms. Based on Modality, the market is segmented into X-RAY, CT, MRI, and Ultrasound. Based on Route of Administration, the market is segmented into Intravascular Route [Intravenous (IV) route, Intra-arterial (IA) route], Oral Route, Rectal Route, and Other Routes. Based on Indication, the market is segmented into Cardiovascular Disease, Cancer, Gastrointestinal Disorders, Musculoskeletal Disorders, Neurological Disorders, and Nephrological Disorders. Based on Application, the market is segmented into Radiology, Interventional Radiology, and Interventional Cardiology. Based on End User, the market is segmented into Hospitals, Clinics, And Ambulatory Surgery Centers, and Diagnostic Imaging Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Contrast Media Market

The global rise in chronic illnesses has led to a substantial increase in the demand for diagnostic imaging procedures and, by extension, contrast media. To address this growing need and to gain approval for new indications, manufacturers of contrast media have been heavily investing in research and development. This investment aims to bring innovative products to the market and enhance their existing offerings. For example, the US FDA approved a new 20-vial pack design of the ultrasound contrast agent Lumason for use by Bracco. This approval reflects the industry's efforts to meet the increasing demand for advanced imaging solutions and to provide healthcare professionals with more effective tools for diagnosing and managing chronic conditions.

Restraints in the Global Contrast Media Market

Contrast agents are widely utilized in various diagnostic techniques, such as MRI and CT scans, due to their ability to enhance imaging clarity. However, the market's growth may be somewhat limited by the potential for adverse effects and allergic reactions associated with their use. Although these negative reactions can vary from mild to severe, it is important to note that severe and major allergic responses are relatively rare.

Market Trends of the Global Contrast Media Market

Iodinated contrast medium is a type of intravenous radiocontrast used to enhance the visibility of vascular systems and organs during radiographic procedures. This contrast medium has been instrumental in detecting conditions such as cancer by improving imaging clarity. The current iodinated contrast media are developed from chemically modified tri-iodinated benzene rings. The effectiveness of iodinated contrast media in attenuating X-rays is influenced by the amount of iodine present in the tissue being imaged, with this attenuation being inversely related to the X-ray energy used. Consequently, the selection and quantity of contrast media needed for specific imaging tasks are based on the desired imaging quality.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Contrast Media Market by Type

Market Overview
Iodinated Contrast Media
Gadolinium-based Contrast Media
Microbubble Contrast Media
Barium-based Contrast Media

Contrast Media Market by Form

Market Overview
Liquid Contrast Media
Powder Contrast Media
Other Forms

Contrast Media Market by Modality

Market Overview
X-RAY
CT
MRI
Ultrasound

Contrast Media Market by Route of Administration

Market Overview
Intravascular Route
- Intravenous (IV) route
- Intra-arterial (IA) route
Oral Route
Rectal Route
Other Routes

Contrast Media Market by Indication

Market Overview
Cardiovascular Disease
Cancer
Gastrointestinal Disorders
Musculoskeletal Disorders
Neurological Disorders
Nephrological Disorders

Contrast Media Market by Application

Market Overview
Radiology
Interventional Radiology
Interventional Cardiology

Contrast Media Market by End User

Market Overview
Hospitals, Clinics, And Ambulatory Surgery Centers
Diagnostic Imaging Centers

Contrast Media Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

GE Healthcare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bracco Imaging SpA (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guerbet (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lantheus Medical Imaging (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Unijules Life Sciences Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
J.B. Chemicals & Pharmaceuticals Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Taejoon Pharm Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jodas Expoim (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Imax Diagnostic Imaging Limited (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Yangtze River Pharmaceutical Group (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Livealth Biopharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beijing Beilu Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Unispire Biopharma Private Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arco Lifesciences (I) Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stanex Drugs & Chemicals Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rege Imaging & Cine Films Private Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
K Diam Exim (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Onko Ilac San. ve Tic. A.S. (Turkey)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biem Ilac San. ve Tic. A.S. (Turkey)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advacare Pharma (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments